MeSH tree: C10.314.350.500
People with insurance through an employer or another commercial plan experienced an average wait time of 50 days for their first visit with a neurology provider, according to a study published in Neurology. Wait times were ...
Apr 29, 2026
0
5
When the U.S. Department of Justice moved to reclassify medical marijuana to a Schedule III drug on April 23, 2026, it set the stage for a vast amount of medical research that has been hobbled for decades by its more restrictive ...
Apr 29, 2026
0
6
The immune system is the frontline protection against infection, continually searching for and destroying unknown pathogens. While typical operation of the immune system scans for threats, some systems attack the body's own ...
Apr 26, 2026
0
12
Damage to white matter in the brain can trigger features associated with neurodegenerative disease, Cambridge researchers have discovered in a new study published in the journal Nature. Until now, it was thought that neurodegenerative ...
Apr 22, 2026
0
6
Researchers at the University of São Paulo (USP) in Brazil discovered that neurodegenerative diseases, such as Alzheimer's, Parkinson's, and multiple sclerosis, are more complex than previously thought. Their analysis of ...
Apr 22, 2026
0
14
For people who see a neurology clinician for the first time, a new study has found that being seen virtually vs. in person made no difference in how soon they needed more care. The work is published in Neurology. For the ...
Apr 22, 2026
0
1
Knowing that women are diagnosed with multiple sclerosis (MS) at three times the rate of men, particularly during their 30s and 40s, scientists in the CU Anschutz lab of Kimberley Bruce, Ph.D., recently took that window of ...
Apr 21, 2026
0
4
The more precisely we want to examine the human retina, the more clearly one of the fundamental limits of physics becomes apparent. In cellular-resolution eye imaging, the same tradeoff has applied for years—tiny structures ...
Apr 20, 2026
0
3
A new U.S. Senate report, released by Sen. Bernie Sanders, found that drug companies involved in price deals with President Donald Trump have continued to raise prices on hundreds of meds.
Apr 20, 2026
0
5
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a form of MS thought to ...
Apr 15, 2026
0
13
